Korea's Celltrion Cuts Deal With Perrigo To Sell Its Biosimilars In Israel
This article was originally published in PharmAsia News
Executive Summary
SEOUL - As part of its bid to stretch out for more global sales for a range of antibody therapeutic biosimilars, Celltrion has signed a deal with Perrigo to market its products in Israel